Vitrectomy and Bevacizumab for Diffuse Diabetic Macular Edema
Information source: Asociación para Evitar la Ceguera en México
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: * Diffuse Diabetic Macular Edema
Intervention: Bevacizumab + Pars plana vitrectomy (Procedure); Bevacizumab + pars plana vitrectomy (Procedure)
Phase: Phase 3
Status: Recruiting
Sponsored by: Asociación para Evitar la Ceguera en México Official(s) and/or principal investigator(s):
Veronica Kon-Jara, MD, Principal Investigator, Affiliation: Asociacion para Evitar la Ceguera en Mexico
Overall contact:
Veronica Kon-Jara, MD, Phone: 5215537291895, Email: veronicakon@yahoo.com
Summary
To Evaluate combined effect of vitrectomy and bevacizumab to stabilize retinal thickness and
visual acuity in patients with diffuse diabetic macular edema and their relation to renal
disease.
Clinical Details
Official title: Pars Plana Vitrectomy and Bevacizumab for the Treatment of Diffuse Diabetic Macular Edema (A Pilot Study)
Study design: Treatment, Randomized, Open Label, Single Group Assignment, Efficacy Study
Primary outcome: Retinal thickness
Secondary outcome: Visual acuity
Eligibility
Minimum age: 25 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Older than 25 yo
- Diffuse diabetic macular edema with or without previous treatment
Exclusion Criteria:
- Another retinal disease
- Pregnancy
Locations and Contacts
Veronica Kon-Jara, MD, Phone: 5215537291895, Email: veronicakon@yahoo.com
Asociacion para Evitar la Ceguera en Mexico I.A.P., Mexico 04030, Mexico; Recruiting
Ma Ana Martinez-Castellanos, MD, Sub-Investigator
Oscar Alvarez-Verduzco, MD, Sub-Investigator
Jose Luis Guerrero-Naranjo, MD, Sub-Investigator
Hugo Quiroz-Mercado, MD, Sub-Investigator
Additional Information
Starting date: November 2007
Ending date: February 2008
Last updated: December 7, 2007
|
